CV Technologies Appoints Two New Directors

EDMONTON, ALBERTA--(Marketwire - Feb. 4, 2008) - CV Technologies Inc. (TSX:CVQ) is pleased to announce the appointment of two new members to its Board of Directors, effective February 1, 2008. These appointments bring the Board complement to 10 Directors.

J. Douglas Gilpin, CA: Mr. Gilpin is a Chartered Accountant with more than 30 years of business advisory and consultancy experience. He was a partner with KPMG LLP from 1981 until his retirement from the firm in 1999. His practice focused on business advisory and assurance matters and involved work with numerous companies in the biotechnology field. Mr. Gilpin is a Director of Canada Health Infoway Inc./Inforoute Sante du Canada, Chairman of its Governance Committee and a member of its Finance, Investment & Audit Committee. He is also a public member of the Finance Investment & Audit Committees for each of Search Canada Inc. and the College of Physicians & Surgeons of Alberta. Mr. Gilpin serves on the Board of Directors of ViRexx Medical Corp. (a TSX listed company) as Chairman of both the Audit Committee and the Governance and Nominating Committee. He will serve as Chair of CV Technologies' Audit Committee.

David T. Weyant, QC: Mr. Weyant is Vice President and General Counsel for the Calgary Health Region, one of the largest fully-integrated, publicly-funded health care systems in Canada. He has been practicing law for over 17 years, both as a litigator and as a corporate/commercial lawyer negotiating transactions including securities, outsourcing, private/public partnerships, lending, financing and other corporate commercial transactions. His expertise is frequently sought on various aspects of risk management, corporate/commercial law, health law, and corporate governance.

He has served on various boards, chaired committees, and served as a member of a provincial commission, the executive of the Association of General Counsel of Alberta, as well as local and national Canadian Bar Association sections. Mr. Weyant is a member of the Institute of Corporate Directors and is currently enrolled in its Directors Education Program. He will join CV Technologies' Corporate Governance and Nominating Committee.

"We look forward to the contributions that Mr. Gilpin and Mr. Weyant will make to achieving CV Technologies' goals," said Gordon Tallman, Chairman of the Board of Directors. "In our industry's complex business environment, scientific excellence is one element essential to success. We also require the extensive strategic, legal, financial, governmental and regulatory knowledge that Messrs. Gilpin and Weyant bring to our Board, based particularly on their broad experience in biotechnology and healthcare."


CV Technologies is a global leader in the development and commercialization of naturally derived, evidence-based, natural therapeutics for disease prevention and health maintenance. Its lead product - COLD-fX® - approved by Health Canada, prevents and relieves cold and flu infections by strengthening the immune system.

This news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results or events to differ materially from the results or events predicted in this release. Potential risks and uncertainties include, without limitation, those associated with product development, future revenues and profitability related to the development and execution of the Company's new business plan. For a more in-depth account of risks and uncertainties, please refer to documents filed with the Canadian securities regulatory authorities through the System for Electronic Document Analysis and Retrieval (SEDAR). Subject to its obligations under applicable law, the Company assumes no duty to update this disclosure. The Company is a 12g3-2(b) SEC registrant.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.